From molecule to the medicine cabinet

Our research division, Forest Research Institute (FRI), drives the development of our novel pharmaceutical agents and provides medical and scientific support for currently marketed products.

The growth of Forest as a company is driven by our R&D productivity. By having steadily increased our R&D investment and deepened our pool of talent over the past decade, Forest has strengthened its ability to license innovative new products earlier in the development cycle and across a wider span of therapeutic areas. Once a compound enters our pipeline, we collaborate closely with our partner to formulate and implement a development plan that will maximize the potential benefits of the drug.

Read further to learn more about our R&D pipeline.